Sesen Bio is a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer. Co.'s main product candidate Vicinium (VB4-845), is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive carcinoma in situ of the bladder in patients previously treated with adequate or less than adequate bacillus Calmette-Guerin. Co.'s lead systemically-administered product candidate, VB6-845d, is being developed as a treatment for multiple types of EpCAM-positive solid tumors. We show 3 historical shares outstanding datapoints in our CARM shares outstanding history coverage, used to compute CARM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CARM market cap history over the course of time is important for investors
interested in comparing CARM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CARM versus a peer is one thing; comparing
CARM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CARM can fluctuate over the course of history.
With this page we aim to empower investors researching CARM by allowing them to research the CARM market cap history. |
Free CARM Email Alerts:
Video: The Importance of Market Cap
